Frank Lopez
Neurodevelopmental Disabilities · Winter Park, FLNPI 1154453397
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $398,228 of the $484,332 with a category attached, or 82.2%. 31 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 59.3% of the total. Reporting peaked in 2019 at $155,823 and has fallen 67.8% since, to $50,208 in 2025.
Across 792 payments — averaging $611.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$287K
- Ironshore Pharmaceuticals Inc.$160K
- Collegium Pharmaceutical, Inc.$15K
- Tris Pharma Inc$9K
- Otsuka America Pharmaceutical, Inc.$7K
- Neos Therapeutics, LP$3K
- plus $3K from 25 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Collegium Pharmaceutical, Inc.$500
What the payments were for
- Consulting fees$23,8935%
- Speaking & faculty fees$398,22882%
- Travel & lodging$43,5489%
- Food & beverage$18,6384%
- Education$50%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 328 | $287,152 |
| Ironshore Pharmaceuticals Inc. | 304 | $160,419 |
| Collegium Pharmaceutical, Inc. | 15 | $15,214 |
| Tris Pharma Inc | 27 | $8,841 |
| Otsuka America Pharmaceutical, Inc. | 9 | $6,820 |
| Neos Therapeutics, LP | 2 | $2,514 |
| Corium, LLC | 1 | $920 |
| UCB, Inc. | 32 | $733 |
| Jazz Pharmaceuticals Inc. | 11 | $272 |
| Neurelis, Inc. | 13 | $259 |
| MDD US Operations, LLC | 1 | $186 |
| Acadia Pharmaceuticals Inc | 7 | $160 |
| Sumitomo Pharma America, Inc. | 7 | $128 |
| Livanova USA, Inc. | 4 | $117 |
| Lilly USA, LLC | 4 | $64 |
| Otter Pharmaceuticals, LLC | 2 | $61 |
| Cranial Technologies, Inc | 5 | $59 |
| Azurity Pharmaceuticals, Inc. | 2 | $58 |
| Catalyst Pharmaceuticals, Inc. | 2 | $48 |
| SK Life Science, Inc. | 2 | $46 |
| Noven Therapeutics, LLC | 2 | $39 |
| Greenwich Biosciences, Inc. | 2 | $34 |
| Biocodex, Inc. | 1 | $30 |
| AbbVie | 1 | $27 |
| Biomarin Pharmaceutical Inc. | 2 | $26 |
| Immedica Pharma US, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| ITF Therapeutics LLC | 1 | $15 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
| Rhodes Pharmaceuticals L.p. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$188,584
- Jornay PM 20mg capsules (Bottle of 100)$102,159
- JORNAY PM$70,134
- Dyanavel XR$8,242
- Quillivant XR$2,612
- Quillichew ER$2,612
- Adzenys XR-ODT$2,500
- Cotempla XR-ODT$2,500
- Azstarys$920
- MYOBLOC$186
How this compares
Too few neurodevelopmental disabilities providers in Floridato place this figure against a meaningful peer group, so we don't.
Other neurodevelopmental disabilities in Winter Park
- Mikhail MirerPensacola$4K
- Michael EnriquezPensacola$2K
- Naina MehtaOrlando$54
- Pamela PapolaPort Charlotte$23
- Joseph CiminoMelbourne$22
- James van DecarEglin Afb$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.